Response to Letter. "Romosozumab and cardiovascular safety- should we learn lessons from Pioglitazone?."

Tominaga, Ayako; Wada, Keiji; Okazaki, Ken; Nishi, Hideharu; Terayama, Yasushi; Kato, Yoshiharu

Tominaga, Ayako; Wada, Keiji; Okazaki, Ken; Nishi, Hideharu; Terayama, Yasushi; Kato, Yoshiharu.

Afiliação

Tominaga A; Department of Orthopedic Surgery, Tokyo Women's Medical University, 8-1 Kawadacho Shinjuku-ku, Tokyo, Japan.
Wada K; Department of Orthopedic Surgery, Tokyo Women's Medical University, 8-1 Kawadacho Shinjuku-ku, Tokyo, Japan. keijiwadajp@yahoo.co.jp.
Okazaki K; Department of Orthopedic Surgery, Tokyo Women's Medical University, 8-1 Kawadacho Shinjuku-ku, Tokyo, Japan.
Nishi H; Hasuda Hospital, 1662-1 Negane Hasudashi, Saitama, Japan.
Terayama Y; Hasuda Hospital, 1662-1 Negane Hasudashi, Saitama, Japan.
Kato Y; Kita Shinagawa 3rd Hospital, 3-3-7 Kitashinagawa Shinagawa-ku, Tokyo, Japan.

Osteoporos Int ; 33(6): 1401-1402, 2022 06.

Article em En | MEDLINE | ID: mdl-35181822

Assuntos

Conservadores da Densidade Óssea; Osteoporose; Anticorpos Monoclonais; Humanos; Pioglitazona

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Osteoporose / Conservadores da Densidade Óssea Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google